Cited by 29Autophagy in Disease and TherapyPancreatic and Hepatic Oncology ResearchCalcium signaling and nucleotide metabolism

Targeting autophagy as a therapeutic strategy against pancreatic cancer

Open access
Yamamoto, Keisuke, Iwadate, Dosuke, Kato, Hiroyuki, Nakai, Yousuke, Tateishi, Keisuke, Fujishiro, Mitsuhiro·2022·Journal of Gastroenterology

Abstract

Macroautophagy (hereafter autophagy) is a catabolic process through which cytosolic components are captured in the autophagosome and degraded in the lysosome. Autophagy plays two major roles: nutrient recycling under starvation or stress conditions and maintenance of cellular homeostasis by removing the damaged organelles or protein aggregates. In established cancer cells, autophagy-mediated nutrient recycling promotes tumor progression, whereas in normal/premalignant cells, autophagy suppresses tumor initiation by eliminating the oncogenic/harmful molecules. Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is refractory to most currently available treatment modalities, including immune checkpoint blockade and molecular-targeted therapy. One prominent feature of PDAC is its constitutively active and elevated autophagy-lysosome function, which enables PDAC to thrive in its nutrient-scarce tumor microenvironment. In addition to metabolic support, autophagy promotes PDAC progression in a metabolism-independent manner by conferring resistance to therapeutic treatment or facilitating immune evasion. Besides to cell-autonomous autophagy in cancer cells, host autophagy (autophagy in non-cancer cells) supports PDAC progression, further highlighting autophagy as a promising therapeutic target in PDAC. Based on a growing list of compelling preclinical evidence, there are numerous ongoing clinical trials targeting the autophagy-lysosome pathway in PDAC. Given the multifaceted and context-dependent roles of autophagy in both cancer cells and normal host cells, a deeper understanding of the mechanisms underlying the tumor-promoting roles of autophagy as well as of the consequences of autophagy inhibition is necessary for the development of autophagy inhibition-based therapies against PDAC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00535-022-01889-1

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Autophagy is elevated in the late stages of PDAC, where it fuels tumour metabolism to promote tumour growth and drug resistance.

    “autophagy is elevated in the late stages of PDAC, where it fuels tumour metabolism to promote tumour growth and drug resistance [47]”

    From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models (2024) · cites this paper as [47]

    The Background describes elevated autophagy in PDAC as supporting growth through nutrient recycling and promoting treatment resistance. It distinguishes established cancer from premalignant cells, but does not establish that autophagy becomes elevated specifically in the late stages of PDAC. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M.
Affiliations
The University of Tokyo (JP)
Corresponding author
Yamamoto, Keisuke
Venue
Journal of Gastroenterology
Published
2022-06-21
Volume
57
Issue
9
Pages
603-618
ISSN
  • 0944-1174 (ISSN-L)
  • 1435-5922
OpenAlex
W4283211173
Cited by
29
References
151
Citations by year
2026: 6 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 2
FWCI
4.15
Type
journal article
Language
en
Open access
Locations
  • Journal of Gastroenterology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Yasuda Memorial Medical Foundation
  • The Tokyo Society of Medical Sciences
  • MSD Life Science Foundation
  • Astellas Foundation for Research on Metabolic Disorders
  • Uehara Memorial Foundation
  • Princess Takamatsu Cancer Research Fund
  • Life Science Foundation of Japan
  • Japan Society for the Promotion of Science (21K20828, 22H02898, 22H03053)
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
Keywords
autophagy, pancreatic ductal adenocarcinoma, autophagy inhibition, autophagy-lysosome pathway, host autophagy, tumor microenvironment, immune evasion, drug resistance, metabolic reprogramming, autophagy-targeted therapy
MeSH terms
Autophagy, Humans, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review